Expertise in
13
conditions

Dr. Jeffrey A. Meyerhardt

Oncology
Dana-Farber Cancer Institute, Center For Gastrointestinal Oncology
450 Brookline Avenue, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
13
conditions
Dana-Farber Cancer Institute, Center For Gastrointestinal Oncology
450 Brookline Avenue, 
Boston, MA 

Overview

Jeffrey Meyerhardt is an Oncologist practicing medicine in Boston, Massachusetts.

Dr. Meyerhardt is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, PIK3CA-Related Overgrowth Spectrum, Pancreatic Cancer, and Pancreaticoduodenectomy.

Dr. Meyerhardt is board certified in Medical Oncology. He is actively involved in clinical research, co-authoring 414 peer reviewed articles and participating in 6 clinical trials. Dr. Meyerhardt is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MA

Board Certifications

Medical Oncology

Fellowships

Dana Farber Cancer Institute******, 2000 - 2002

Hospital Affiliations

Brigham And Women's Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Trustmark
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute, Center for Gastrointestinal Oncology
450 Brookline Avenue, Boston, MA 02115
Other Locations
Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street, Chestnut Hill, MA 02459

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2026
Intervention Type: Drug, Radiation
Study Drugs: Tremelimumab, Durvalumab
Study Phase: Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Colorectal Cancer
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Pilot Study of Physical Activity in Older Adults With Metastatic Gastrointestinal Cancer
A Pilot Study of Physical Activity in Older Adults With Metastatic Gastrointestinal Cancer
Enrollment Status: Completed
Publish Date: March 12, 2020
Intervention Type: Other
Study Phase: Not Applicable
View 5 Less Clinical Trials

414 Total Publications

Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM).
Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM).
Journal: JCO oncology advances
Published: August 18, 2026
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Davids is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Davids is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Tissue Biopsy. Dr. Davids is currently accepting new patients.

Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Abramson is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Abramson is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Abramson is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Toni Choueiri is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Choueiri is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Urothelial Cancer, Nephrectomy, and Orchiectomy. Dr. Choueiri is currently accepting new patients.

Frequently Asked Questions about Dr. Jeffrey A. Meyerhardt

How do I make an appointment with Dr. Jeffrey A. Meyerhardt?

You can book an appointment with Dr. Jeffrey A. Meyerhardt by calling their office at 617-632-6855. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey A. Meyerhardt a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey A. Meyerhardt is classified as an Elite expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey A. Meyerhardt specialize in?

While Dr. Jeffrey A. Meyerhardt is a Oncology, they have specific expertise in Colorectal Cancer, Familial Colorectal Cancer, and PIK3CA-Related Overgrowth Spectrum. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jeffrey A. Meyerhardt participate in research or clinical trials?

Yes. Dr. Jeffrey A. Meyerhardt has published 414 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Jeffrey A. Meyerhardt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jeffrey A. Meyerhardt accept my insurance?

Dr. Jeffrey A. Meyerhardt accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-632-6855 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Meyerhardt's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile